INTERCEPT PHARMACEUTICALS, INC.
DelistedCIK 1270073fmd_1YBYATRR2118WJG5HWVVP2P648Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2023, 54 periods
| Line item | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 2 | 3 | 25 | 131 | 180 | 252 | 234 | 261 | 286 |
| Cost of revenue | – | – | – | – | 1 | 3 | 4 | 2 | 1 | 1 |
| Gross profit | – | – | – | – | 130 | 177 | 248 | 232 | 260 | 285 |
| Research and development | 28 | 80 | 113 | 154 | 191 | 207 | 243 | 189 | 183 | 177 |
| Selling, general and administrative | – | 35 | 119 | 274 | 274 | 255 | 317 | 261 | 177 | 176 |
| Total operating expenses | – | 115 | 232 | 427 | 467 | 465 | – | – | – | – |
| Operating income | – | (113) | (229) | (403) | (336) | (285) | (312) | (230) | (100) | (68) |
| Interest expense | – | – | – | 14 | 29 | 31 | 41 | 48 | 54 | 21 |
| Other non-operating income (expense) | (28) | (170) | 3 | (10) | (25) | (24) | (32) | (44) | (36) | (107) |
| Income before taxes | (68) | (283) | (226) | (413) | (360) | (309) | (345) | (273) | (136) | (175) |
| Net income from continuing operations | – | – | – | – | – | – | – | (273) | (136) | (175) |
| Net income | (68) | (283) | (226) | (413) | (360) | (309) | (345) | (275) | (91) | 222 |
| Net income to common shareholders | (68) | (283) | (226) | (413) | (360) | – | – | – | – | – |